• Global resolution secures patient access to Sandoz biosimilar Hyrimoz^® (adalimumab)[1] for the reference medicine Humira^®**
• Resolution paves way for 2018 launch in key European markets and secures US market entry planned in 2023

Holzkirchen, October 11, 2018 – Sandoz, a Novartis division and the global leader in biosimilars, today announced a global resolution of all intellectual property (IP) related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz^® (adalimumab)[1] for …